These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19232285)

  • 21. Multidimensionality of symptom complexes in irritable bowel syndrome and other functional gastrointestinal disorders.
    Alpers DH
    J Psychosom Res; 2008 Jun; 64(6):567-72. PubMed ID: 18501256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options in irritable bowel syndrome.
    Farthing MJ
    Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):773-86. PubMed ID: 15324713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Irritable Bowel Syndrome; gut microbiota and probiotic therapy].
    Tojo González R; Suarez Gonzalez A; Rúas Madiedo P; Mancebo Mata A; Pipa Muñiz M; Barreiro Alonso E; Roman Llorente FJ; Moro Villar MC; Arce González MM; Villegas Diaz MF; Mosquera Sierra E; Ruiz Ruiz M
    Nutr Hosp; 2015 Feb; 31 Suppl 1():83-8. PubMed ID: 25659060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.
    Quigley EM; Flourie B
    Neurogastroenterol Motil; 2007 Mar; 19(3):166-72. PubMed ID: 17300285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets.
    Dupont HL
    Aliment Pharmacol Ther; 2014 May; 39(10):1033-42. PubMed ID: 24665829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets.
    Dahlqvist G; Piessevaux H
    Acta Gastroenterol Belg; 2011 Sep; 74(3):375-80. PubMed ID: 22103040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal microbiota, pathophysiology and translation to probiotic use in patients with irritable bowel syndrome.
    Almansa C; Agrawal A; Houghton LA
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):383-98. PubMed ID: 22646259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definition and epidemiology of functional gastrointestinal disorders.
    Corazziari E
    Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):613-31. PubMed ID: 15324703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of pathogenic microbes and commensal bacteria in irritable bowel syndrome.
    Collins S; Verdu E; Denou E; Bercik P
    Dig Dis; 2009; 27 Suppl 1():85-9. PubMed ID: 20203502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probiotics and diverticular disease.
    Sheth A; Floch M
    Nutr Clin Pract; 2009; 24(1):41-4. PubMed ID: 19244147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The rationale for antibiotics in IBS.
    Di Stefano M; Corazza GR
    Am J Gastroenterol; 2008 Oct; 103(10):2652. PubMed ID: 18855859
    [No Abstract]   [Full Text] [Related]  

  • 33. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Fronzoni L; Serra M; Corinaldesi R
    Dig Dis; 2009; 27 Suppl 1():115-21. PubMed ID: 20203507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of probiotics in IBD and IBS.
    De Greef E; Vandenplas Y; Hauser B; Devreker T; Veereman G
    Minerva Pediatr; 2014 Oct; 66(5):491-500. PubMed ID: 25243502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probiotics in functional bowel disorders.
    Hod K; Ringel Y
    Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):89-97. PubMed ID: 27048900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with enteric-coated peppermint oil reduced small-intestinal bacterial overgrowth in a patient with irritable bowel syndrome.
    Gaby AR
    Altern Med Rev; 2003 Feb; 8(1):3; author reply 4-5. PubMed ID: 12611555
    [No Abstract]   [Full Text] [Related]  

  • 37. Bacterial concepts in irritable bowel syndrome.
    Lin HC; Pimentel M
    Rev Gastroenterol Disord; 2005; 5 Suppl 3():S3-9. PubMed ID: 17713456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR.
    Malinen E; Rinttilä T; Kajander K; Mättö J; Kassinen A; Krogius L; Saarela M; Korpela R; Palva A
    Am J Gastroenterol; 2005 Feb; 100(2):373-82. PubMed ID: 15667495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characterization of intestinal function and diagnosis of irritable bowel syndrome by surveys and questionnaires].
    Drossman DA
    Gastroenterol Clin Biol; 1990; 14(5 ( Pt 2)):37C-41C. PubMed ID: 2210182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study.
    Parry SD; Stansfield R; Jelley D; Gregory W; Phillips E; Barton JR; Welfare MR
    Am J Gastroenterol; 2003 Feb; 98(2):327-31. PubMed ID: 12591050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.